Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases-Reference-Cited by-同舟云学术

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases

Published:2023-03-13 Issue:6 Volume:66 Page:4025-4044
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Guo Yunhang¹^ORCID,Hu Nan²,Liu Ye³,Zhang Wei¹,Yu Desheng¹,Shi Gongyin¹,Zhang Bo³,Yin Longbo²,Wei Min³,Yuan Xi⁴,Luo Lusong⁴,Wang Fan⁵,Song Xiaomin²,Xin Lei¹,Wei Qiang¹,Li Yong¹,Guo Ying³,Chen Shuaishuai⁴,Zhang Taichang⁵,Zhang Shuo²,Zhou Xing³,Zhang Cuining⁶,Su Dan⁵,Liu Junhua¹,Cheng Zhenzhen⁴,Zhang Jiye²,Xing Haimei⁴,Sun Hanzi³,Li Xin⁶,Zhao Yuan⁴,He Min²,Wu Yue⁵,Guo Yin⁴,Sun Xuebing³,Tian Alice⁶,Zhou Changyou¹^ORCID,Young Steve¹,Liu Xuesong⁴,Wang Lai²,Wang Zhiwei¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China

2. Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China

3. Department of Molecular Science, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China

4. Department of Discovery Biology, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China

5. Department of DMPK-BA, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China

6. Department of Nonclinical Safety Assessment, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01938

Reference49 articles.

1. Trends in kinase drug discovery: targets, indications and inhibitor design

2. The resurgence of covalent drugs

3. Advances in covalent drug discovery

4. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

5. Signalling of Bruton's Tyrosine Kinase, Btk